An intelligent nanoreservoir system promotes heart valve regeneration via ROS scavenging and immunomodulation
Source abstract
Abstract
In situ regeneration of tissue-engineered heart valves (TEHV) is a promising strategy to overcome the limitations of existing heart valve prostheses. Although, decellularized aortic valves (DAVs) are widely regarded as a scaffold in the construction of TEHV, the poor hemocompatibility and adverse immune responses make DAV scaffolds prone to thrombosis and degradation, thus hindering recellularization and in situ regeneration. Our study developed an immune-regulatory strategy involving the use of hydrogel-encapsulated nanoparticles to modify DAV scaffolds. Specifically, folic acid- and hyaluronic acid-modified mesoporous silica nanoparticles (FA-HA-MSNs@CY-09) were engineered to deliver NOD-like receptor family, pyrin domain containing 3 (NLRP3) inhibitor CY-09, thereby targeting macrophages, modulating their polarization and establishing a pro-regenerative immune microenvironment. The reactive oxygen species (ROS)-responsive hydrogel delivering FA-HA-MSNs@CY-09 enabled intelligent nanoparticle release and ROS scavenging. Results demonstrated that the hydrogel-modified DAV scaffold exhibited ROS-responsive release of FA-HA-MSNs@CY-09, which effectively induced macrophage polarization toward the pro-remodeling M2 phenotype. In vitro, the scaffold showed favorable mechanical properties, cytocompatibility, and hemocompatibility. Transcriptome sequencing elucidated the macrophage-reprogramming mechanism of the scaffold. In vivo, the scaffolds promoted significant M2 macrophage infiltration shortly after implantation, facilitating endothelial tissue formation. This resulted in enhanced endothelialization and interstitial cell infiltration under blood flow, without thrombosis or calcification. The novel heart valve overcomes various limitations of conventional heart valve prostheses and demonstrates considerable promise for clinical translation, particularly as an immunomodulatory biomaterial strategy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cardiac Valve Diseases and Treatments · Cardiac and Coronary Surgery Techniques · Cardiac Structural Anomalies and Repair
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity10.1038/s41569-020-0422-8 ↗
2. Global epidemiology of valvular heart disease10.1038/s41569-021-00570-z ↗
3. 2021 ESC/EACTS guidelines for the management of valvular heart disease10.1093/eurheartj/ehab395 ↗
4. Designing biocompatible tissue engineered heart valves in situ: JACC review topic of the week10.1016/j.jacc.2022.12.022 ↗
5. Facile engineering of interactive double network hydrogels for heart valve regeneration10.1038/s41467-024-51773-0 ↗
6. Modifying decellularized aortic valve scaffolds with stromal cell-derived factor-1α loaded proteolytically degradable hydrogel for recellularization and remodeling10.1016/j.actbio.2019.02.002 ↗
7. Strategies for development of decellularized heart valve scaffolds for tissue engineering10.1016/j.biomaterials.2022.121675 ↗
8. Pioneering a paradigm shift in tissue engineering and regeneration with polysaccharides and proteins-based scaffolds: a comprehensive review10.1016/j.ijbiomac.2024.130643 ↗
9. Nitric oxide generation and endothelial progenitor cells recruitment for improving hemocompatibility and accelerating endothelialization of tissue engineering heart valve
10. Immune responses to implants - a review of the implications for the design of immunomodulatory biomaterials10.1016/j.biomaterials.2011.05.078 ↗
11. Mechanisms of organ injury and repair by macrophages10.1146/annurev-physiol-022516-034356 ↗
12. ECM-mimetic immunomodulatory hydrogel for methicillin-resistant Staphylococcus aureus-infected chronic skin wound healing10.1126/sciadv.abn7006 ↗
13. Reactive oxygen species in macrophages: sources and targets10.3389/fimmu.2021.734229 ↗
14. A versatile drug-controlled release polymer brush hybrid non-glutaraldehyde bioprosthetic heart valves with enhanced anti-inflammatory, anticoagulant and anti-calcification properties, and superior mechanical performance10.1016/j.biomaterials.2023.122070 ↗
15. Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering - do patient characteristics warrant precision engineering?10.1016/j.addr.2021.113960 ↗
16. Mechanism and regulation of NLRP3 inflammasome activation10.1016/j.tibs.2016.09.002 ↗
17. Ponatinib drives cardiotoxicity by S100A8/A9-NLRP3-IL-1β mediated inflammation10.1161/CIRCRESAHA.122.321504 ↗
18. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders10.1084/jem.20171419 ↗
19. Platelet-targeted thromboprophylaxis with a human serum albumin fusion drug: preventing thrombosis and reducing cardiac ischemia/reperfusion injurywithout bleeding complications10.7150/thno.97517 ↗
20. Carrier systems for advanced drug delivery: improving drug solubility/bioavailability and administration routes10.3390/pharmaceutics16070852 ↗
21. Engineered pH-Responsive mesoporous carbon nanoparticles for drug delivery10.1021/acsami.0c01786 ↗
22. Powering mesoporous silica nanoparticles into bioactive nanoplatforms for antibacterial therapies: strategies and challenges10.1186/s12951-023-02093-w ↗
23. Ultrasound responsive mesoporous silica nanoparticles for biomedical applications10.1039/C8CC09389J ↗
24. Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms10.1038/s41392-023-01499-0 ↗
25. Hyaluronic acid-functionalized mesoporous silica nanoparticles loading simvastatin for targeted therapy of atherosclerosis10.3390/pharmaceutics14061265 ↗
26. Exosomes loaded a smart bilayer-hydrogel scaffold with ROS-scavenging and macrophage-reprogramming properties for repairing cartilage defect
27. Layer-by-Layer cerium oxide nanoparticle coating for antioxidant protection of encapsulated beta cells10.1002/adhm.201801493 ↗
28. Bioactive mesoporous silica nanoparticle-functionalized titanium implants with controllable antimicrobial peptide release potentiate the regulation of inflammation and osseointegration10.1016/j.biomaterials.2023.122465 ↗
29. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery10.1002/adma.201104763 ↗
30. Sequential hydrophile and lipophile solubilization as an efficient method for decellularization of porcine aortic valve leaflets: structure, mechanical property and biocompatibility study10.1002/term.2388 ↗
31. ROS-scavenging hydrogel to promote healing of bacteria infected diabetic wounds10.1016/j.biomaterials.2020.120286 ↗
32. In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy10.1126/scitranslmed.aan3682 ↗
33. Large-scale surface modification of decellularized matrix with erythrocyte membrane for promoting in situ regeneration of heart valve10.1016/j.eng.2024.04.019 ↗
34. Development of transcatheter tissue-engineered heart valves with dual crosslinking and nitric oxide releasing decellularized matrix composites for in-situ regeneration10.1016/j.compositesb.2024.112048 ↗
35. Cellular RNA and DNA sensing pathways are essential for the dose-dependent response of human monocytes to ionizing radiation10.3389/fimmu.2023.1235936 ↗
36. The upregulation of regenerative activity for extracellular vesicles with melatonin modulation in chemically defined media10.3390/ijms232315089 ↗
37. Biomaterials strategies to balance inflammation and tenogenesis for tendon repair10.1016/j.actbio.2021.05.043 ↗
38. Chitosan degradation products facilitate peripheral nerve regeneration by improving macrophage-constructed microenvironments10.1016/j.biomaterials.2017.02.026 ↗
39. Reprogram to heal: macrophage phenotypes as living therapeutics10.1016/j.lfs.2025.123601 ↗
40. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway10.1038/s41467-020-20154-8 ↗
41. Antifibrotic effects of tetrahedral framework nucleic acids by inhibiting macrophage polarization and macrophage-myofibroblast transition in bladder remodeling10.1002/adhm.202203076 ↗
42. Intracellular and extracellular synergistic therapy for restoring macrophage functions via anti-CD47 antibody-conjugated bifunctional nanoparticles in atherosclerosis
43. A novel mechanism of resveratrol alleviates Toxoplasma gondii infection-induced pulmonary inflammation via inhibiting inflammasome activation10.1016/j.phymed.2024.155765 ↗
44. AIM2 forms a complex with pyrin and ZBP1 to drive PANoptosis and host defence10.1038/s41586-021-03875-8 ↗
45. Studies of hematopoietic cell differentiation with a ratiometric and reversible sensor of mitochondrial reactive oxygen species10.1089/ars.2015.6495 ↗
46. Exosomes derived from LPS-preconditioned bone marrow-derived MSC modulate macrophage plasticity to promote allograft survival via the NF-κB/NLRP3 signaling pathway10.1186/s12951-023-02087-8 ↗
47. Pyroptotic macrophage-derived microvesicles accelerate formation of neutrophil extracellular traps via GSDMD-N-expressing mitochondrial transfer during sepsis10.7150/ijbs.87646 ↗
48. Anti-IL-17 inhibits PINK1/Parkin autophagy and M1 macrophage polarization in rheumatic heart disease10.1007/s10753-024-02094-3 ↗
49. An emodin-mediated multifunctional nanoplatform with augmented sonodynamic and immunoregulation for osteomyelitis therapy10.1016/j.jcis.2025.01.094 ↗
50. Serine ubiquitination of SQSTM1 regulates NFE2L2-dependent redox homeostasis10.1080/15548627.2024.2404375 ↗
51. Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy10.1016/j.addr.2015.09.009 ↗
52. Injection of ROS-responsive hydrogel loaded with IL-1β-targeted nanobody for ameliorating myocardial infarction
53. Strategies for development of synthetic heart valve tissue engineering scaffolds10.1016/j.pmatsci.2023.101173 ↗
54. Bioprosthetic heart valve structural degeneration associated with metabolic syndrome: mitigation with polyoxazoline modification10.1073/pnas.2219054120 ↗
55. Hybrid heart valves with VEGF-loaded zwitterionic hydrogel coating for improved anti-calcification and re-endothelialization, materials today
56. Development of antithrombogenic ECM-based nanocomposite heart valve leaflets10.1021/acsabm.2c00423 ↗
57. Thrombosis in the setting of obesity or inflammatory bowel disease10.1182/blood-2016-05-716720 ↗
58. Plasma proteomic profile associated with platelet dysfunction after trauma10.1111/jth.15316 ↗
59. Inhibition of LDHA to induce eEF2 release enhances thrombocytopoiesis10.1182/blood.2022015620 ↗
60. Inhibition of IP3 (Inositol 1,4,5-Trisphosphate) Receptors Retards SARS-CoV-2-Induced Endothelial von Willebrand Factor Secretion and Thrombosis
61. The secreted tyrosine kinase VLK is essential for normal platelet activation and thrombus formation10.1182/blood.2020010342 ↗
62. DMAG, a novel countermeasure for the treatment of thrombocytopenia
63. Focal adhesion kinases in platelet function and thrombosis10.1161/ATVBAHA.118.311787 ↗
64. Qihuang Zhuyu formula alleviates coronary microthrombosis by inhibiting PI3K/Akt/αIIbβ3-mediated platelet activation10.1016/j.phymed.2023.155276 ↗
65. The role of Rac1 in glycoprotein Ib-IX-mediated signal transduction and integrin activation10.1161/ATVBAHA.112.254920 ↗
66. Tailoring surface nanoroughness of electrospun scaffolds for skeletal tissue engineering10.1016/j.actbio.2017.07.003 ↗